Paula
Rodríguez Otero
Consultora Médica
![Foto de Paula](/img/nophoto.png)
![Foto de Institute Catalá Oncología](/img/noimage_org.png)
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (6)
2024
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
2022
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2021
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Blood Cancer Journal, Vol. 11, Núm. 6
2020
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469